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Abstract
Endothelial colony-forming cells (ECFCs) are a defined subtype of endothelial progenitors that modulate vascular repair and promote perfusion
in ischaemic tissues. Their paracrine activity on resident vasculature is ill-defined, but mediated, at least in part, by the transfer of extracellular
vesicles (EVs). To evaluate the potential of isolated EVs to provide an alternative to cell-based therapies, we first performed a physical and
molecular characterization of those released by ECFCs. Their effects upon endothelial cells in vitro and angiogenesis in vivo in a model of prolif-
erative retinopathy were assessed. The EVs expressed typical markers CD9 and CD63 and formed a heterogeneous population ranging in size
from ~60 to 1500 nm by electron microscopy. ECFC EVs were taken up by endothelial cells and increased cell migration. This was reflected by
microarray analyses which showed significant changes in expression of genes associated with angiogenesis. Sequencing of small RNAs in
ECFCs and their EVs showed that multiple microRNAs are highly expressed and concentrated in EVs. The functional categories significantly
enriched for the predicted target genes of these microRNAs included angiogenesis. Intravitreally delivered ECFC EVs were associated with the
vasculature and significantly reduced the avascular area in a mouse oxygen-induced retinopathy model. Our findings confirm the potential of
isolated EVs to influence endothelial cell function and act as a therapy to modulate angiogenesis. The functions associated with the specific
microRNAs detected in ECFC EVs support a role for microRNA transfer in mediating the observed effects.
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Introduction
With an ageing population and increased prevalence of diabetes and
hypertension, ischaemic vascular diseases, such as peripheral artery
disease [1], myocardial infarction, and ischaemic retinopathies, are a
growing health issue. Timely promotion of reparative angiogenesis is
an attractive therapeutic approach and preferable to blocking the later
uncontrolled neovascularization which is so damaging, particularly in
the retinopathies. Administration of endothelial progenitor cells with
defined phenotype and vasoreparative phenotype [2], known as
endothelial colony-forming cells (ECFCs), has been demonstrated to
protect against acute kidney injury [3], peripheral artery disease [1]
and reduce ischaemia in animal models of hindlimb ischaemia [4] or
ischaemic retinopathy [5].
Although ECFCs have been reported to incorporate into new ves-
sels [5], their vasoregenerative effects have also been attributed to
paracrine actions [3, 6] mediated, at least in part, by extracellular
vesicles (EVs). Recognition of the therapeutic potential of EVs from
mesenchymal and neural stem cells and cardiac and endothelial pro-
genitor cells [7, 8] has made them the focus of intense study. They
have been demonstrated to transfer proteins, mRNAs, and micro-
RNAs to recipient cells [9–15] and have the ability to modulate
endothelial cell behaviour in vitro [16–19] and angiogenesis in vivo
[18, 20]. Translation of EV-associated mRNAs can occur in recipient
cells [9] and has been implicated in the activation of an angiogenic
programme in endothelial cells [17]. However, EVs carry predomi-
nantly small RNAs, of which microRNAs form a significant proportion
[9, 12]. We and others have demonstrated that many microRNAs are
enriched within the RNA isolated from EVs relative to the originating
cells, suggesting that microRNAs may be selectively incorporated into
EVs [21, 22]. Intercellular transfer of these microRNAs via EVs can
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regulate the gene expression [23] and function of recipient cells [10,
11, 24]. Administration of ECFC exosomes protects against ischaemic
acute kidney injury [3] and the microRNA content of these exosomes,
specifically miR-486-5p, contributes to this protective effect [11].
EVs can be classified into two main types: exosomes, which
are ~50–120 nm in size and released when endosomal multi-
vesicular bodies fuse with the plasma membrane, and ectosomes
(also known as microvesicles or shedding vesicles), which are
generally larger (~50–1500 nm) and are formed by budding from
the plasma membrane [8, 15, 25–27]. In this study, we use the
term ‘EVs’ to refer to the total population of vesicles isolated by
ultracentrifugation. The heterogeneity of EVs, which vary in size
and content between cell types, provides a challenge for the iso-
lation of a defined product with potential as a therapeutic agent
[8]. We have therefore begun to characterize ECFC EVs by study-
ing their morphology, microRNA content, uptake and effect upon
endothelial gene expression.
When the blood supply to the retina is impaired, this can result in
uncontrolled proliferation of new, leaky blood vessels. The resultant
loss of vision is experienced in several eye diseases, including dia-
betic retinopathy, retinal vein occlusion and retinopathy of prematu-
rity. Current therapeutic strategies aimed at blocking the proliferation
include inhibiting VEGF; however, there are mounting concerns over
the long-term effects of chronic VEGF inhibition. If administration of
EVs collected from ECFCs can promote vascular regeneration, this
approach could provide a cell-free alternative to cell-based therapies
that are hampered by low survival rates and the risk of stem cell
tumorigenesis [28]. We demonstrate the ability of EVs injected into
the vitreous to reach the retinal vasculature and reduce the avascular
area in a mouse model of proliferative retinopathy.
Materials and methods
Cell culture
ECFCs were isolated under full ethical approval from umbilical cord
blood (~5 ml) of volunteers at the Royal Victoria Hospital, Maternity
Unit, Belfast, UK. Isolation followed a protocol described previously [2,
5]. Density gradient centrifugation was employed to isolate the mononu-
clear cell layer, which was resuspended in EGM-2 medium supple-
mented with growth factors (EGM-2 Endothelial Growth SingleQuot;
Lonza, Slough, UK) with 12% foetal calf serum (FCS) and incubated on
collagen-coated plates. After 24 hrs, mononuclear cells (MNCs) were
washed with EGM-2 medium to remove any non-adherent cells. MNCs
were cultured for up to 4 weeks with media changed every 48 hrs. Cells
of a cobblestone appearance with a highly proliferative nature appeared
after 2–4 weeks of culture. The identity of ECFCs was confirmed by
immunophenotyping for a combination of markers used to distinguish
ECFCs from other mononuclear cells: endothelial markers CD-31 and
CD-105, haematopoietic markers CD-45 and CD-14 and progenitor mak-
ers CD-34 and CD-117 (Fig. S1). From this point, all supplemented FCS
was depleted of EVs by ultracentrifugation for 18 hrs at 100,000 9 g
(Type P28S rotor, HITACHI, JP-K value 217).
Human retinal microvascular endothelial cells (h.RMECs) were obtained
from Cell Systems (Kirkland, WA, USA). Cells were grown on gelatine-
coated flashes, in CSC-complete medium (4Z0-500; Cell Systems). Human
microvascular endothelial cells (HMEC-1) were provided by Francisco Can-
dal [29] and were cultured in MCDB supplemented with 10% foetal bovine
serum (FBS), L-glutamine (2 mM), epidermal growth factor (10 ng/ml),
hydrocortisone (1 lg/ml) and antibiotics as described previously [29].
Isolation of EVs
Extracellular vesicles were prepared from ECFC cell culture medium by
differential centrifugation. Briefly, conditioned media (containing vesicle-
depleted FCS) were harvested after 48 hrs, centrifuged at 3500 9 g for
30 min. to eliminate cells and at 10,000 9 g (Himac CP100WX Ultra-
centrifuge; Hitachi, Tokyo, Japan) in a swing bucket rotor (P28S; Hita-
chi) for 30 min. to eliminate cellular debris. Vesicles were pelleted by
ultracentrifugation at 100,000 9 g for 120 min. (K value 217). The EV
pellet was resuspended in PBS and repelleted at 100,000 9 g for 2 hrs
at 4°C. The collected EVs were either stored at 80°C or stained using
CM-DiI lipid membrane stain (stock 1 mg/ml, 2.5 ll per ml of PBS)
(Thermo Fisher Scientific, Waltham, MA, USA). EVs were washed twice
in PBS and collected by ultracentrifugation at 100,000 9 g for
120 min.
Transmission Electron Microscopy
Pellets comprising EVs obtained by ultracentrifugation were prepared
for TEM following collection either directly or from the resulting pellet
of binding to 4 lm CD63-coated latex beads. EVs were fixed in 2.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) for 1 hr. Fol-
lowing post-fixation with 1% osmium tetroxide (0.1 M sodium cacody-
late buffer, pH 7.4, at room temperature for 1 hr), the pellet was
washed for 3 9 10 min. in 0.1 M sodium cacodylate buffer (pH 7.4).
The sample was dehydrated by several washes of increasing ethanol
concentration. Finally, the sample was washed twice with dry 100%
ethanol for 30 min. A 1:1 ratio of dry ethanol to Agar low viscosity
resin (LVR) (Agar Scientific, Essex, UK) was added. After 30 min., fur-
ther Agar LVR was added to a final 1:2 ratio and left overnight under
gentle movement to allow ethanol to evaporate off. The Agar LVR resin
was polymerized at 60°C until the resin hardened. Ultrathin sections
were obtained on a Leica Ultracut and collected on copper grids (Agar
Scientific). Grids were stained with saturated alcoholic uranyl acetate
and aqueous lead citrate. Stained sections were viewed with a JEOL
100CXII transmission electron microscope.
Flow cytometry
Flow cytometry was performed according to the method of L€asser et al.
[30]. Briefly, 4-lm latex beads (Aldehyde/Sulfate Latex Beads 4 lm;
Thermo Fisher Scientific) were coated with anti-CD63 antibody (BD Bio-
sciences, Oxford, UK). For each sample (antibody), EVs were added at a
volume equal to a minimum of 15 lg of EV protein to ~100,000 beads.
The beads and EVs were incubated at 4°C overnight under gentle move-
ment. To block, the beads were incubated with 300 ll of 200 mM gly-
cine for 30 min. The beads were washed (PBS containing 2% FCS) at
600 9 g for 10 min., and this was repeated for a total of two washes.
EVs were then stained against antibody of choice (CD63 eBioscience
12-0639, CD9 eBioscience 1:20); after washing, the EV–bead complexes
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Fig. 1 Characterization of endothelial colony-forming cells (ECFC)-derived extracellular vesicles (EVs). (A) Isolated ECFC-derived EVs were conjugated to
CD63-coated latex beads to aid detection by flow cytometry. The gated bead-bound population (left panel) tested positive for EV markers CD9 and CD63.
(B) Electron micrograph demonstrating the heterogeneity of the EV population (scale bar 1 lm). (C) Higher-magnification electron micrograph showing
EVs of variable sizes and including a multivesicular body (scale bar 200 nm). (D–F) Electron micrographs of EVs bound to latex beads (LB) coated with
anti-CD63 antibody. (D) White arrows indicate CD63-positive EVs of varying sizes (scale bar 1 lm). (E) Higher-magnification micrograph of EVs (scale
bar 200 nm). In (F), a multivesicular body appears to be encapsulated within a CD63-positive membrane (scale bar 200 nm).
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were resuspended in 500 ll PBS and assessed using a flow cytometer
(Attune Acoustic Focusing Cytometer; Thermo Fisher Scientific).
Protein extraction
EV protein was extracted using radioimmunoprecipitation assay (RIPA)
buffer supplemented with cOmplete Mini, EDTA-free, Protease Inhibitor
Cocktail (Roche, Burgess Hill, UK). Quantification was performed using a
Micro BCATM Protein Assay Reagent Kit (Thermo Fisher Scientific). The
protein concentrations were used to determine the dose of EVs delivered
in subsequent experiments.
RNA extraction
Total RNA (including small RNAs) was isolated from cells and EVs
using the miRNeasy mini kit according to the manufacturer’s protocol
Fig. 2 Uptake of labelled endothelial col-
ony-forming cells (ECFC) extracellular
vesicles (EVs) by hRMECs. (A) ECFC EVs
labelled with DiI (red) were incubated for
1, 3, 6 or 12 hrs with h.RMECs labelled
with calcein (green cytoplasm) and DAPI
(blue nuclei). Colocalization of red and
green dyes indicates that the vesicles
were internalized by specific individual
cells, whereas other cells remained unla-
belled. (B) The number of cells containing
EVs increased with time. There was a lin-
ear increase in the number of cells
labelled with DiI as incubation times
increased (P < 0.0001, ANOVA with post-
test for linear trend) and the cells also
appeared more brightly labelled. This is a
representative experiment showing the
mean from n = 5 fields for each time-
point (error bars represent standard
error). (C) Internalized ECFC EVs (surface
rendered pink near to nuclei, green further
away) were frequently observed localized
to one side of the recipient h.RMEC
nucleus (blue) (scale bar 10 lM).
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(Qiagen, Crawly, UK). RNA quantity and quality were assessed using
the Qubit (Thermo Fisher Scientific, UK) and Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA, USA), respectively.
Illumina Bead Chip array
EVs were harvested from ECFC-conditioned media after 48 hrs of incuba-
tion. EVs isolated from ECFC-conditioned medium (T75 flask) were added
to HMEC-1 cells (T25 flask) and incubated for 48 hrs. Total RNA was
extracted as above from three independent samples of untreated or EV-
treated cells and gene expression analysis was performed using the
HumanHT-12_V4 array from Illumina (San Diego, CA, USA) following the
manufacturer’s instructions. Gene expression data obtained from Illumina
Beadstudio were normalized using ‘R’ Bioconductor with ‘lumi’ package
[31]. Functional analysis of genes with >1.5-fold altered expression was
performed using Ingenuity Pathway Analysis (IPA; Qiagen).
Small RNA sequencing and analysis
Three ECFC clones were cultured and RNA extracted from the cells
and EVs collected from their cell culture medium. One library was pre-
pared from cellular RNA and one from EV RNA from each of the three
clones using the Truseq small RNA Kit (Illumina), and DNA sequencing
was carried out on a MiSeq in the GenePool genomics facility in the
University of Edinburgh (https://genomics.ed.ac.uk/). FastQ files were
trimmed and aligned to MiRBase version 21 [32] (using the CLC
Genomics workbench 9.0.1 (Qiagen)), allowing a maximum of two
mismatches and five nucleotides shorter or longer than the mature
sequence (RNA-Seq data sets summarized in Table S1). All microRNAs
both 5p and 3p represented by at least 10 reads in total across all
samples were retained for further analysis. Empirical analysis of
differential gene expression was performed with the ‘exact test’ for
two-group comparisons developed by Robinson and Smyth and imple-
mented in the EdgeR package [33]. MicroRNA target genes were
Fig. 3 Endothelial colony-forming cells (ECFC)-derived extracellular vesicles (EVs) promote migration of h.RMECs. (A) Representative images of
scratch wound assays to assess the effect of ECFC EVs (5, 10, 15 lg/ml and no EV control) upon h.RMEC migration. (B) A significant difference
(***P ≤ 0.05) was observed between the no EV control and each ECFC-derived EV treatment (n = 3, error bars represent standard error).
ª 2017 The Authors.
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predicted using IPA with information from TargetScan, miRecords, and
TarBase [34, 35].
Vesicle uptake studies
h.RMECs were stained with calcein (Thermo Fisher Scientific) and
incubated with DiI-stained EVs. Cells were fixed in 4% paraformalde-
hyde for 10 min. at room temperature, followed by two PBS washes.
Cover slips were then mounted on glass slides using mounting
media containing the nuclear stain DAPI (Vectashield; Vector Labora-
tories, Peterborough, UK) and imaged using a Nikon inverted micro-
scope TE2000-U with confocal unit C1 (Nikon, Surrey, UK). For
quantification, five fields were selected randomly. Samples assessed
using the Leica TCS SPS II were additionally stained with TO-PRO-
3 (Thermo Fisher Scientific).
Oxygen-induced retinopathy model
All experiments conformed to U.K. Home Office regulations (Project
Licence No. 2611) and were approved by Queen’s University Belfast
Ethical Review Committee for Animal Research. Oxygen-induced
retinopathy (OIR) was conducted in C57/BL6J wild-type mice accord-
ing to the protocol of Smith et al. In this model, seven-day-old (P7)
mouse pups and their nursing dams were exposed to 75% oxygen
Table 1 Most altered genes in endothelial cells treated with endothelial colony-forming cells extracellular vesicles (EVs) as determined by
microarray
Gene symbol* Mean control Mean EV-treated Fold change
SERPINB2 2.63411 3.3392 5.07
TPM2 2.875 3.5333 4.553
FOXD1 2.94311 3.5516 4.059
MMP1 2.9084 3.5055 3.954
SERPINB2 2.4888 3.0631 3.752
MIR1974 2.7794 3.3509 3.728
TMEM200A 2.63601 3.1849 3.539
DSE 2.5991 3.1376 3.455
TMEM154 2.6664 3.1985 3.404
TPM2 3.3014 3.8096 3.222
MIR1978 3.30111 3.7876 3.065
FBLN2 2.8572 3.3401 3.04
ACVRL1 3.1429 2.6265 3.283
CD34 3.09659 2.5676 3.38
EDN1 3.20119 2.6508 3.551
BGN 3.9473 3.3693 3.784
CCL2 3.4507 2.8375 4.103
AIF1L 3.7038 3.0686 4.317
SULF1 3.0162 2.364 4.489
CRYAB 3.403 2.7049 4.989
ITM2A 3.06829 2.3437 5.303
ALDH1A1 3.4686 2.5408 8.468
ALDH1A1 3.53339 2.5101 10.55
*Genes appearing more than once are represented by independent probes in the microarray.
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(humidified medical-grade oxygen controlled by an Oxycycler C42 (Bio-
Spherix, Parish, NY, USA)) for 5 days causing vaso-obliteration and
cessation of development of the central retinal capillary beds. On post-
natal day 12 (P12), the mice were returned to room air, after which
there was acute retinal ischaemia in the avascular regions of the cen-
tral retina, followed by a potent pre-retinal neovascular response
between P15 and P21.
Intravitreal injection
At P13, pups (n = 11) received a 1 lL intravitreal injection in the
right eye (2 lg of protein content) which had been labelled with
DiI-CM (Thermo Fisher Scientific). PBS was used as vehicle and
injected in the left eye of each pup as a control. All pups were
killed at P17 with sodium pentobarbital, and eyes were enucleated
and fixed in 4% paraformaldehyde. Retinal flat mounts were
stained with isolectin B4 (Sigma-Aldrich, Gillingham, UK) and strep-
tavidin-Alexa Flour488 (Thermo Fisher Scientific). Nuclei were coun-
terstained with TO-PRO-3 (Thermo Fisher Scientific). Stained flat
mounts were imaged with a Leica SP5 confocal microscopy. Multi-
ple images per retina with magnification 910 were stitched
together and the neovascular and avascular areas quantified using
NIS elements software (Nikon). For cell identification, antibodies
(IBA1 (Wako), CD31 and F4/80 (Bio-Rad, Watford, UK)) were used
following the manufacturer’s recommendations.
Statistical analyses
To assess vesicle uptake, one-way ANOVA with post-test for linear trend
was performed using Prism (GraphPad, La Jolla, CA, USA). Cell migra-
tion and retinal avascular and neovascular areas were assessed using
t-tests performed in Prism.
Results
ECFC cell and EV phenotyping
Isolated ECFCs tested highly positive for endothelial markers CD-31
and CD-146, whereas it tested negative for haematopoietic markers
CD-45 and CD-14 (Fig. S1). These results are comparable with previ-
ously characterized ECFC [5] and suggest that these cells possess an
endothelial phenotype.
Table 2 Significantly altered functional categories
Categories Diseases or functions annotation P-value
Cardiovascular system development and function Development of vasculature 6.12E-26
Cardiovascular system development and function, organismal development Angiogenesis 3.17E-24
Cellular growth and proliferation Proliferation of cells 2.37E-22
Cardiovascular system development and function, organismal development Vasculogenesis 2.34E-21
Cellular movement Cell movement 5.86E-19
Cell death and survival Necrosis 1.04E-18
Tissue development Growth of epithelial tissue 2.82E-18
Cardiovascular system development and function, cellular development, cellular
function and maintenance, cellular growth and proliferation,
organismal development, tissue development
Endothelial cell development 3.41E-18
Cell death and survival Apoptosis 8.34E-18
Cellular movement Migration of cells 2.80E-17
Cardiovascular system development and function, cellular development,
cellular function andmaintenance, cellular growth and proliferation,
organismal development, tissue development
Proliferation of endothelial cells 1.10E-16
Cardiovascular system development and function, cellular movement Cell movement of endothelial cells 2.66E-16
Cell death and survival Cell death 2.90E-16
Tissue development Development of epithelial tissue 7.83E-16
Cardiovascular system development and function, cellular movement Migration of endothelial cells 8.11E-15
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EVs isolated from ECFCs were first characterized by surface
immunophenotyping for known vesicle markers CD9 and CD63.
These tetraspanins were chosen because their expression across a
broad range of tissues and abundance in vesicle membranes has
made them classical markers of exosomes. However, they are also
widely distributed in the plasma membrane and therefore present
in other vesicles [36], with CD9 reported in large vesicles [37] and
detected by flow cytometry in both microvesicles and exosomes
[38]. To aid in the detection of EVs by flow cytometry, they were
bound to aldehyde/sulphate latex beads, which had been pre-coated
with anti-CD63 antibody to enable adhesion of CD63-positive EVs.
These EV–bead complexes were then immunostained for CD9 and
CD63. Flow cytometric analysis of ECFC-derived EV–bead com-
plexes showed a distinct population of beads with an average over-
all signal from bound EVs that were positive for these EV markers
(Fig. 1A).
ECFCs release a diverse population of EVs
To assess the size range and morphology of isolated ECFC-derived
EVs, TEM was performed. This revealed an extremely diverse and
complex population of EVs, varying in both morphology and
diameter (Fig. 1B–F). Ranging in size from 60 to 120 nm in diame-
ter with electron-dense interiors, many of the EVs are consistent
with characteristics reported for exosomes [12, 15, 27]. A small
number of EVs with more electron-dense structures and a diameter
of approximately 60 nm may be a subpopulation of exosomes. The
more numerous larger EVs have diameters of 140–1500 nm and
lack an electron-dense interior characteristics of ectosomes (mi-
crovesicles) [12, 15].
A fourth population of EVs was associated with more than one
membrane. Some appeared as a large electron lucid vesicle contain-
ing one or more smaller electron-dense vesicles, similar to the multi-
vesicular bodies reported to be released from other cell types [39].
There were rare occurrences of a single vesicle encapsulated within
many layers of membranes, similar to those reported in human blood
[40], ejaculates [41] and mouse lymph [42]. TEM was used to investi-
gate the morphology of the CD63-positive EVs bound to anti-CD63-
coated aldehyde/sulphate latex beads detected by flow cytometry. As
with the previous TEM analysis of all the EVs present in the pellet col-
lected by ultracentrifugation, a diverse population of EVs were
observed bound to CD63-coated beads. The CD63+ EVs displayed a
similar range of sizes and morphologies (Fig. 1D–F). This included a
multivesicular body encapsulated within an outer membrane
(Fig. 1F).
-
-
Fig. 4 Addition of extracellular vesicles (EVs) is predicted to alter the activity of functional categories associated with ‘cellular movement’. For
functional categories significantly enriched in altered genes, as detected by microarray following treatment of hRMECs with EVs, both the direc-
tion of change and predicted effect of each gene were considered. Migration and transmigration of myeloid cells, transendothelial migration of
monocytes and transmigration of leucocytes were predicted to be decreased in activity (activation z-score <2). The six categories most likely
to be enhanced in activity (activation z-score 1-1.5) included migration of microvascular endothelial cells, cell movement of endothelial cell lines
and endothelial cell.
8 ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
Interaction and uptake of ECFC EVs by h.RMECs
To assess the potential for ECFC-derived EVs to influence angiogene-
sis, their interactions with human retinal microvascular endothelial
cells (h.RMEC), a key target cell type, were investigated. Confocal
microscopy imaging of h.RMECs after incubation with EVs labelled
with DiI confirmed their cellular uptake (Fig. 2A). Some cells appeared
to contain large quantities of EVs, whereas others had no detectable
internalized EVs. The number of h.RMECs taking up EFCF EVs was not
dose dependent, but the fluorescence intensity of positive cells
increased with dose of labelled EVs (data not shown). EVs were
observed as both small and large aggregated clumps within the perin-
uclear region, as reported previously [43], and were often located pri-
marily to one side of the nucleus (Fig. 2C, Fig. S2). To determine the
effect of time of exposure to EVs upon uptake, the number of cells
containing EVs was measured at several time-points over a 12-hrs
period. Pre-stained ECFC EVs were added at T0 and imaged at time-
points up to 12 hrs. No EVs were detected in cells prior to one hour of
incubation; thereafter, the number of cells containing EVs was calcu-
lated as a percentage. The percentage of cells that had taken up EVs
increased with time, suggesting that a subset of the h.RMEC cell popu-
lation is receptive to EFCF EV uptake in a time-dependent manner.
Cells also became brighter in the red channel (DiI-stained EVs) with
time, presumably due to additional vesicles being taken up by recep-
tive cells (similarly, incubation with higher concentrations of EVs also
increased cell fluorescence (data not shown)).
ECFC EVs promote h.RMEC migration
A scratch was generated in a monolayer of confluent h.RMECs as
described previously [44], and the effect of ECFC-derived EVs was
assessed. The effect of three concentrations of ECFC-derived EVs (5,
10 and 15 lg/ml) upon wound closure was assessed in comparison
with no EV controls. There was a significant difference (P ≤ 0.05)
observed between percentage of wound closure after 6 hrs in the no
EVs control (20%) and 5 lg/ml (28%), 10 lg/ml (27.5%) and 15 lg/
ml (38%) treatments (Fig. 3). This suggests that ECFC-derived EVs
can confer a pro-migratory potential to h.RMECs.
Influence of ECFC EVs upon endothelial gene
expression
Global changes in gene expression caused by incubation of human
microvascular endothelial cells with ECFC EVs for 48 hrs were mea-
sured by microarray. Expression of 674 genes was altered with a
fold change of ≥1.5 in either direction (P < 0.05), with 284
increased and 390 reduced. The ten most altered genes in either
direction are shown in Table 1, and the complete list is provided in
Data S1. Several genes amongst those most increased are involved
in extracellular matrix (ECM) remodelling, matrix metalloproteinase
1 (MMP1), which is involved in the degradation of ECM, and fibulin
2 (FBLN2). The heparan sulphate-modifying enzyme SULF1, which
Table 3 MicroRNAs identified in cells and extracellular vesicles (EVs) ranked by expression
MicroRNA
Cells—Normalized
mean counts
MicroRNA
EVs—Normalized
mean counts
mir-10b-5p 280,851 mir-10b-5p 334,402
mir-21-5p 192,847 mir-30a-5p 94,312
mir-30a-5p 94,476 mir-21-5p 45,939
mir-10a-5p 46,992 mir-22-3p 41,936
mir-126-5p 23,631 mir-486-2-5p 36,424
mir-22-3p 23,134 mir-486-1-5p 32,501
let-7i-5p 19,915 mir-151a-3p 29,859
mir-151a-3p 16,003 mir-126-5p 24,546
mir-92a-1-3p 15,570 mir-10a-5p 22,513
mir-92a-2-3p 14,682 mir-25-3p 18,841
mir-222-3p 13,653 let-7i-5p 15,672
mir-21-3p 13,438 mir-221-3p 15,626
let-7f-2-5p 11,289 mir-216a-5p 14,126
let-7f-1-5p 10,951 mir-92a-1-3p 12,689
mir-28-3p 9673 mir-92a-2-3p 12,614
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Table 4 MicroRNAs differentially expressed >fivefold between cells and vesicles with total normalized expression >500 counts
MicroRNA
Cells—Normalized
mean counts
EVs—Normalized
mean counts
Fold change
(Vesicles/Cells)*
Bonferroni p value
miR-4532-5p 1 1555 561.9 2.0E-15
miR-451a-5p 4 2298 313.0 2.7E-28
miR-7704-5p 28 4077 111.8 6.5E-13
miR-486-2-5p 284 36,424 93.4 1.0E-20
miR-486-1-5p 263 32,501 90.9 2.4E-22
miR-4792-5p 40 3291 76.7 7.5E-14
miR-4516-5p 5 689 72.6 1.0E-11
miR-3960-3p 6 757 70.7 9.5E-13
miR-1246-5p 36 3068 56.7 7.6E-16
miR-320b-1-3p 10 633 36.9 2.6E-13
miR-216a-5p 333 14,126 35.5 3.1E-09
miR-320b-2-3p 13 593 29.9 2.1E-12
miR-143-3p 306 6615 16.1 6.4E-12
miR-380-3p 28 472 15.0 7.7E-07
miR-107-3p 515 8223 13.0 7.0E-11
miR-432-5p 173 2372 11.1 1.5E-09
miR-323a-3p 95 843 7.1 9.4E-05
miR-134-5p 327 2241 5.6 6.3E-05
miR-660-5p 233 1456 5.6 2.8E-03
miR-20a-5p 613 79 6.2 4.1E-04
miR-151a-5p 2166 505 6.5 1.6E-04
miR-30c-2-5p 581 109 6.8 4.8E-04
miR-26b-5p 814 106 6.9 9.4E-05
miR-30c-1-5p 597 104 7.7 3.3E-04
miR-26a-2-5p 2531 524 8.2 6.2E-04
miR-31-5p 4069 540 8.3 3.0E-05
let-7f-1-5p 10,951 1689 8.4 5.5E-09
let-7f-2-5p 11,289 1644 8.7 1.9E-09
miR-26a-1-5p 2552 433 9.9 3.5E-05
let-7g-5p 2710 239 12.8 1.0E-10
let-7a-1-5p 7768 772 14.4 3.0E-12
miR-1260a-5p 882 111 15.0 2.8E-05
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mediates heparan sulphate–VEGFA interactions and inhibits angio-
genesis [45], was down-regulated by EVs. Also down-regulated are
ACVRL1—mutations in which cause vessel malformations in hered-
itary haemorrhagic telangiectasia [46]—endothelin 1 (EDN1), which
encodes vasoconstrictive peptides, and CCL2, which has chemotac-
tic activity for monocytes and basophils.
The most significantly enriched functional categories amongst
those genes with altered expression (>1.5) are listed in Table 2, the
two most significant being ‘development of vasculature’ and ‘angio-
genesis’. Of those categories for which it was possible to predict a
direction of effect based on prior knowledge of the causal effects of
the genes involved, the most decreased (activation
z-score <2) involved in migration of myeloid cells (Data S2),
whereas the most activated involved in cell proliferation and cancer.
When considering functional categories associated with ‘cellular
movement’, although migration and transmigration of myeloid cells,
transendothelial migration of monocytes and transmigration of leuco-
cytes were significantly enriched in altered genes and predicted to be
decreased in activity (activation z-score <2), the six categories most
likely to be enhanced in activity (activation z-score 1–1.5) included
migration of microvascular endothelial cells, cell movement of
endothelial cell lines and endothelial cell chemotaxis (Fig. 4).
Table 4. Continued
MicroRNA
Cells—Normalized
mean counts
EVs—Normalized
mean counts
Fold change
(Vesicles/Cells)*
Bonferroni p value
let-7a-2-5p 7738 715 15.2 4.9E-13
let-7a-3-5p 7755 677 15.8 1.1E-13
miR-181a-1-3p 4929 348 17.4 8.6E-09
let-7d-5p 990 41 18.3 1.8E-10
let-7e-5p 2673 118 21.1 8.6E-12
miR-27a-5p 589 20 25.3 4.8E-04
miR-100-3p 726 25 26.0 4.6E-05
miR-374a-3p 833 22 29.4 5.5E-11
EVs, extracellular vesicles.
*Fold change from EDGE test (tagwise dispersions).
Fig. 5MicroRNAs differentially expressed between cells and vesicles. The volcano plot highlights all microRNAs differentially expressed between
endothelial colony-forming cells (ECFC) cells and vesicles (Bonferroni-corrected P values <0.05). The colour of each spot indicates the expression
level (blue low, red high) of the microRNA that they represent. The identities of the most significantly different and highly exported (e.g. miR-451
and miR-486-5p) or retained (members of the let7 family) microRNAs are labelled.
ª 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
11
J. Cell. Mol. Med. Vol XX, No X, 2017
MicroRNA content of ECFC vesicles
Small RNA sequencing was used to identify the profiles of micro-
RNAs present within ECFCs and exported in their vesicles. The 15
most highly expressed microRNAs identified in cells and EVs are
listed in Table 3 (all microRNAs listed in Data S3). Those moderate
to highly expressed microRNAs (mean normalized expression com-
bined between cells and vesicle >200 reads) differentially expressed
between cells and vesicles (Bonferroni-corrected P values <0.01)
are shown in Table 4. A volcano plot highlighting all microRNAs
differentially expressed between the compartments (Bonferroni-cor-
rected P values <0.05, Fig. 5) shows that many of the most highly
exported (e.g. miR-451 and miR-486-5p) and retained (members of
the Let7 family) microRNAs concur with previous findings for
ECFCs [11] and other cell types [21]. The microRNA expression
profiles of independent samples of EVs are more similar to one
another than the profiles from a specific ECFC clone and its EVs
(Fig. S3), suggesting that a conserved subset of microRNAs is
exported.
MicroRNAs work combinatorially to regulate gene expression
[47], and indeed, many genes are targeted by multiple microRNAs.
The genes predicted to be targeted by those microRNAs most highly
expressed in EVs (top 15 microRNAs comprising ~75% of all reads,
Table 3) are most significantly enriched in the functional category
‘metastasis’, with ‘development of vasculature’, ‘angiogenesis’ and
‘cell movement of endothelial cells’ also within the top 10 categories
(Data S4). The microRNAs enriched in EVs (>threefold, >100 reads)
have an overlapping list of predicted target genes that are significantly
enriched in diseases or functions associated with cancer. To try and
identify the most likely functional interactions, the predicted targets
were compared with those genes down-regulated in endothelial cells
following treatment with EVs (Data S1). This identified 16 genes
(listed in Data S5), which pathway analysis showed to be enriched in
functions associated with ‘cardiovascular system development and
function’. Notable individual genes include CDH5 (VE-cadherin),
reduction of which causes endothelial cells to adopt a migratory phe-
notype [48], and IGFBP5 that has been linked to endothelial cellular
senescence [49].
Fig. 6 Endothelial colony-forming cells (ECFC) extracellular vesicles (EVs) target perivascular cells and reduce avascular area in an oxygen-induced
retinopathy (OIR) model. (A-C) ECFC EVs labelled with DiI (red) were injected into the vitreous of 13-day-old (P13) mouse pups following exposure
to high oxygen. The pups were culled during the subsequent neovascular response at P17 and retinal flat mounts prepared. Red EVs were visible
close to the vasculature visualized with endothelial marker CD31 (green) (A). Use of microglia/macrophage markers F4/80 (B) or Iba1 (C) showed
EVs associated with perivascular cells (scale bar 10 lm). (D, E) To assess avascular area, retinal flat mounts prepared from eyes injected with vehi-
cle control or EVs were stained with isolectin (green) to identify the vasculature. The central avascular area is delineated with a blue line. (F) There
was a significant decrease in the avascular area in retinas injected with ECFC EVs (P ≤ 0.05) compared with vehicle (n = 9 in each group).
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ECFC EVs contribute to vascular repair in the
retina
EVs injected into the vitreous were detectable in the retina of the OIR
model of diabetic retinopathy. The EVs were associated with endothe-
lial cells and perivascular cells, including some that stained positive
for macrophage and microglial markers F4/80 and IBA1 (Fig. 6,
Fig. S4). A significant decrease (P ≤ 0.05) in the avascular area at
P17 was observed in mice injected with EVs versus vehicle control at
P13 (Fig. 6), although the decrease in neovascular area was not sig-
nificant (Fig. S5).
Discussion
The molecular and functional assays reported in this study confirm
the potential of ECFC EVs to modulate endothelial cell behaviour
and influence angiogenesis in vivo, supporting previous reports
that exosomes from ECFCs can block human umbilical vein
endothelial cell apoptosis and protect against acute kidney injury
[3]. It therefore seems plausible that EVs could be used as the
basis of a cell-free therapy for ischaemic diseases that could pro-
vide many of the benefits already demonstrated for direct applica-
tion of ECFC cells [8]. In addition to removing any risk of
neoplastic transformation, the potential advantages of this strategy
include the ability to genetically engineer the contents and employ
the diverse EV constituents to target multiple mechanisms simulta-
neously [8].
However, the diversity of EV populations presents a challenge for
defining appropriate subsets for therapeutic use. The electron micro-
scopy in this study confirmed that the diversity, both in size and in
morphology, of the vesicles released by ECFCs is similar to that
reported from many other cell types and observed in biofluids [12,
41, 50]. This is exemplified by the observation of vesicles comprising
several membranes, similar to those reported elsewhere [39, 50]. The
close interactions observed between the membranes of vesicles
>1 lm and anti-CD63 beads suggest that CD63 is not exclusively an
exosome marker and support reports of its association with additional
EV populations [51]. A prerequisite for clinical applications will be
development of robust protocols for the isolation of better defined EV
populations.
Fluorescently labelled EVs were taken up by endothelial cells over
a period of hours and localized in the perinuclear region [43, 52].
Although over 50% of cells internalized EVs in vitro, a much smaller
subpopulation was positive in the retina. It is encouraging that EVs
were detectable in regions of ischaemia/angiogenesis following
intravitreal delivery. This is an advantage to minimize potentially dele-
terious side effects from systemic delivery. ECFCs have been manipu-
lated to improve homing to appropriate cells, for example, by
overexpression of integrin b1 [1], and a similar strategy could be
adopted for EVs.
The observation from small RNA sequencing data that certain
microRNAs are enriched in EVs relative to ECFC cells (more
extremely than in the reverse direction) is consistent with
preferential loading of specific microRNAs. Although the functions
of most of these EV-enriched microRNAs are unknown, several
have been implicated in vascular function. Exosome-derived miR-
486-5p targets the phosphatase and tensin homolog (PTEN) in
endothelial cells and reduces ischaemic kidney injury [11]. Con-
versely, miR-26a, which is retained within ECFC cells, inhibits EC
migration and angiogenesis [53]. Although the mechanism by
which specific microRNAs are loaded into EVs is not well under-
stood, it is possible to manipulate the microRNA content of EVs
by modulating expression in the parental cells [21]. This approach
has already been reported for let7c in mesenchymal stem cells
[54] and miR-486-5p in ECFC EVs [11]. The small RNA sequenc-
ing data presented here provide further candidate microRNAs for
development of this strategy to enhance the therapeutic properties
of EVs.
The molecular characterization of ECFC EVs and demonstration of
their efficacy in an in vivo model provide support for their develop-
ment as a therapy for retinal ischaemic disease.
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